CJC-1295 Peptide | Growth Hormone & Performance

Overview

CJC-1295 demonstrates superior stability compared to native GHRH through strategic amino acid modifications that eliminate DPP-4 cleavage sites while preserving GHRH receptor binding affinity. The peptide exists in two forms: CJC-1295 with Drug Affinity Complex (DAC) providing extended half-life, and CJC-1295 without DAC offering more physiological pulsatile release patterns. The compound is metabolized primarily through peptidase enzymes and eliminated via renal excretion.

Chemical structure & Properties

• Molecular Formula: C165H271N47O46

• Molecular Weight: 3,647.28 Da

• Sequence: Modified GRF(1-29) with Lys substitution and maleimido-propionyl-Lys attachment

• Half-life: 6-8 days (with DAC), 30 minutes (without DAC)

• Stability: Enhanced resistance to DPP-4 degradation through amino acid modifications

Regulatory Status and

Legal Considerations

FDA Status

• Classification: Investigational peptide - not approved for therapeutic use

• Approval Status: No FDA approval for human clinical applications

• Research Use: Limited to approved clinical trials and research protocols

• Regulatory Position: Previously nominated to Category 2. Listed as Nominated but Withdrawn from Category 2 as of April 22, 2026. Standard 503A/503B pharmacy regulations now apply. Not approved for therapeutic use.

WADA Status

• Classification: Prohibited under S2: Peptide Hormones, Growth Factors

• Athletic Use: Banned in competitive sports and athletic competitions

• Testing: Detectable through specialized anti-doping analysis methods

• Enforcement: Subject to sporting sanctions and competition disqualification

Legal Availability

• Commercial Status: Not legally available as prescription medication

• Market Presence: Available through research chemical suppliers and compounding pharmacies

• Quality Control: Limited regulatory oversight for purity, potency, and authenticity

• Clinical Use: Restricted to research institutions and experimental protocols

The Paragon Method: Step-by-Step

Clinical Considerations

Important Guidelines:

• No FDA-approved dosing recommendations exist for human use

• Individual response varies based on age, health status, and baseline hormone levels

• Regular monitoring of IGF-1 levels recommended to prevent excessive elevation

• Medical supervision strongly advised for any therapeutic application

• Quality and purity of research chemicals cannot be guaranteed

Priority Research Areas

Clinical Development Priorities:

• Large-scale, placebo-controlled trials for various therapeutic indications

• Long-term safety studies including comprehensive carcinogenicity assessment

• Optimal dosing protocols and treatment duration guidelines

• Combination therapy studies with other peptides and hormones

• Age-specific efficacy and safety evaluations

Emerging Applications

Investigational Uses:

• Age-related sarcopenia and frailty prevention

• Post-surgical recovery and wound healing enhancement

• Metabolic syndrome and insulin resistance management

• Cognitive function preservation and neuroprotection

• Osteoporosis prevention and bone health optimization

• Sleep disorders and circadian rhythm normalization

Combination Therapies

Synergistic Research:

• CJC-1295 plus Ipamorelin for enhanced GH release

• Integration with testosterone replacement therapy

• Combination with other regenerative peptides (BPC-157, TB-500)

• Synergistic effects with lifestyle interventions and exercise protocols

Conclusion

CJC-1295 represents a promising long-acting growth hormone-releasing hormone analog with demonstrated efficacy in stimulating endogenous GH and IGF-1 secretion. Its unique pharmacokinetic profile and favorable safety data distinguish it as a potential therapeutic tool for growth hormone optimization, body composition enhancement, and anti-aging applications.

However, the current clinical evidence base remains limited, with most data derived from small-scale, short-term studies. The lack of FDA approval, regulatory restrictions, and limited long-term safety data necessitate careful consideration and medical supervision for any therapeutic application.

Patients considering CJC-1295 therapy should engage in thorough discussions with qualified healthcare providers to weigh potential benefits against risks and explore evidence-based treatment alternatives. Future research will be critical in determining CJC-1295's role in clinical medicine, particularly in healthy aging, metabolic disorders, and hormone optimization protocols. Until comprehensive clinical trials are completed, its use should remain limited to research settings under appropriate medical oversight.

CJC-1295 SCIENTIFIC

DATA SUMMARY

Parameter

Molecular Weight

Amino Acid Length

Half-Life

Bioavailability

Detection Window

Value

3,647.28 Da

30 residues (modified)

6-8 days (with DAC), 30 min (without DAC)

High subcutaneous, negligible oral

Up to several weeks (depending on form)

Application

GH Stimulation

Body Composition

IGF-1 Elevation

Metabolic Effects

Studies

10+ studies

8+ studies

12+ studies

6+ studies

Dose Range

30-60 μg/kg

1-2 mg/dose

1-2 mg/dose

1-2 mg weekly

Outcome

6-10x GH increase, sustained 12+ hours

Increased lean mass, reduced adiposity

50-70% increase in serum IGF-1 levels

Enhanced osteoblast activity, BMD increase

Study Type

Phase I Efficacy (Teichman)

GHRH-KO Mouse Study

Protein Profile Study

Population

24 healthy adults

GH-deficient mice

Normal adult subjects

Results

GH increased from 3 to 20 ng/mL

Complete growth normalization

Significant GH/IGF-1 axis activation

Limitations

Short-term, small sample

Animal model, not human

Biochemical endpoints only

Parameter

Acute Toxicity

Organ Toxicity

Adverse Events

Long-term Safety

Finding

No serious adverse events at therapeutic doses

No significant organ-specific toxicity reported

Injection site reactions, mild fluid retention

Limited data beyond 6-month treatment periods

Authority

FDA

WADA

DEA

Classification

Investigational Peptide

S2 Peptide Hormones

Unscheduled

Status

Not approved for human use

Prohibited in sports

Not controlled substance

Peptides work best as one part of a complete, medically supervised plan. These are often used alongside our medically supervised weight loss program in Atlanta. To see how this fits your goals, explore our full approach to peptide therapy in Atlanta.

Disclaimer: This information is provided for educational purposes only and does not constitute medical advice. CJC-1295 is not approved by the FDA for human therapeutic use. Patients should consult with qualified healthcare providers before considering any peptide therapy.

The content reflects current scientific literature and regulatory status as of April 22–23, 2026.

Explore Peptide Therapy at Paragon

Peptides work best as part of a bigger plan, not on their own. At Paragon Sports Medicine in Atlanta, every peptide is prescribed by our team, guided by your labs and your goals, and matched to the right protocol for you. If you are wondering whether this one fits where you want to go, our peptide therapy program in Atlanta is the place to start.